文献速递前列腺癌

循环肿瘤DNA致病性基因组改变可预测转移性去势抵抗性前列腺癌总生存

Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2025-08-06

本研究基于III期试验A031201中776例mCRPC患者,使用AR-ctDETECT检测ctDNA致病性遗传改变(PGAs),并构建临床-遗传(CG)模型预测总生存(OS)。CG模型平均tAUC为0.77(95%CI 0.73-0.79),优于临床模型0.72(95%CI 0.69-0.75,p=0.01),NRI为0.29;风险分组中位OS分别为19.6、33.6和60.8个月。

要点

  • ctDNA PGAs纳入CG模型可改善mCRPC患者OS预测。
  • CG模型平均tAUC 0.77,临床模型0.72,p=0.01。
  • 风险分组中位OS:差19.6月、中33.6月、低60.8月。

核心结论

  • 将ctDNA致病性基因组改变纳入CG模型,较临床模型改善OS预测近30%。
  • CG模型可将患者分为不同风险组,有助于未来mCRPC试验筛选患者。

研究设计与样本

  • 分析Alliance III期试验A031201中776例mCRPC患者的ctDNA。
  • 使用AR-ctDETECT检测PGAs,采用随机生存森林进行特征选择。
  • 通过NRI评估CG模型增量价值,tAUC评估OS模型准确性。

主要发现

  • 特征选择识别出AR、AR增强子、MYC、RSPO2、CCND1、BRAF、MET获得性改变。
  • 识别出ZBTB16、PTEN、MSH6、PPP2R2A、NKX3-1、ZFHX3、TP53、ZNFR3、RB1、FANCA、CHECK1、APC、CHD1缺失或致病性变异及致病性AR变异。
  • CG模型平均tAUC为0.77(95%CI 0.73-0.79),临床模型为0.72(95%CI 0.69-0.75,p=0.01)。
  • CG模型与临床模型间NRI为0.29。
  • 按预测风险评分分为差、中、低风险组,中位OS分别为19.6、33.6、60.8个月。

关键数值与推荐

  • CG模型平均tAUC 0.77(95%CI 0.73-0.79)。
  • 临床模型平均tAUC 0.72(95%CI 0.69-0.75,p=0.01)。
  • NRI为0.29。
  • 差、中、低风险组中位OS分别为19.6、33.6、60.8个月。

临床怎么用

  • 可利用ctDNA PGAs构建CG模型对mCRPC患者进行OS风险分层。
  • 该模型有助于未来mCRPC临床试验的患者筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Although validated prognostic models exist for men with metastatic castration-resistant prostate cancer (mCRPC), current tools do not incorporate genomic biomarkers such as circulating tumor DNA (ctDNA) aneuploidy or pathogenic genetic alterations (PGAs). This study aimed to estimate the prevalence of PGAs in ctDNA, assess their correlation with ctDNA aneuploidy fraction, and evaluate their association with overall survival (OS). Additionally, we developed and validated a clinical-genetic (CG) model to predict OS. METHODS: We analyzed ctDNA from 776 patients enrolled in the Alliance phase 3 trial (A031201). PGAs were derived using the AR-ctDETECT assay. The net reclassification improvement (NRI) evaluated the added value of the CG model, and the time-dependent area under the receiver operating characteristic curve (tAUC) assessed the accuracy of the OS model. KEY FINDINGS AND LIMITATIONS: Feature selection using random survival forest identified gains in androgen receptor (AR), AR enhancer, MYC, RSPO2, CCND1, BRAF, and MET; losses or pathogenic variants in ZBTB16, PTEN, MSH6, PPP2R2A, NKX3-1, ZFHX3, TP53, ZNFR3, RB1, FANCA, CHECK1, APC, and CHD1; and a pathogenic AR variant. The CG model significantly outperformed the clinical model, with an average tAUC of 0.77 (95% confidence interval [CI]: 0.73-0.79) for the CG model compared with the tAUC of 0.72 (95% CI: 0.69-0.75, p = 0.01) for the clinical model, and NRI of 0.29 between the models. Patients were categorized by the predicted risk scores into poor-, intermediate-, and low-risk groups with median OS of 19.6, 33.6, and 60.8 mo, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Incorporation of PGAs from ctDNA into a CG model improved OS prediction by nearly 30% over a clinical model. This model can classify patients into risk groups and is useful for selecting patients in future mCRPC trials.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Halabi S, Guo S, Luo B, et al. Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. Eur Urol. 2025. PMID: 40774853. doi:10.1016/j.eururo.2025.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。